1. Immunology/Inflammation
  2. MyD88

ST 2825 

Cat. No.: HY-50937 Purity: 99.51%
Handling Instructions

ST 2825 is a MyD88 homodimerization inhibitor.

For research use only. We do not sell to patients.
ST 2825 Chemical Structure

ST 2825 Chemical Structure

CAS No. : 894787-30-5

Size Price Stock Quantity
10 mM * 1 mL in DMSO USD 1905 In-stock
1 mg USD 426 In-stock
5 mg USD 1464 In-stock
10 mg USD 2227 In-stock
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

Customer Review

    ST 2825 purchased from MCE. Usage Cited in: Mol Med Rep. 2015 Jul;12(1):895-904.

    The degradation of IκBα and nuclear translocation of p65 induced by IL-1β are also dramatically blocked by pretreatment of the cells with TLR2Ab, ST2825 and TPCA-1. The cultured leukocytes are obtained from a normal control mouse and stimulated with IL-1β (10 ng/ml) for 1 h with or without pre-treatment of BML-111 (1 mM) for 30 min, BOC1 (100 μM) for 30 min, TLR2Ab (1 μg/mL) for 1 h, goat IgG (1 μg/mL) for 1 h, ST2825 (20 μM) for 1 h or TPCA-1 (10 μM) for 1 h. The western blot is representative

    ST 2825 purchased from MCE. Usage Cited in: Genet Mol Res. 2016 Mar 4;15(1):15016826.

    Effect of ST2825 on IκB, cyclin D1, cleaved caspase-3, and bcl-2 expression in HepG-2 cells as determined by western blot analysis (lane 1, blank; lane 2, control; and lane 3, high-dose ST2825). Compared with the control, 24 h of ST2825 treatment significantly inhibits cyclin D1 and bcl-2 expression (P>0.05), but 24-h treatment with ST2825 significantly increases cleaved caspase-3 expression (P<0.05) in the high-dose group.

    ST 2825 purchased from MCE. Usage Cited in: Brain Res. 2016 Jul 15;1643:130-9.

    Effect of ST2825 treatment on the expression of MyD88 at 24h after TBI. Levels of MyD88 are significantly increased at 24 h after TBI. ST2825 (20 μg/μL) treatment reduces the levels of MyD88 at 24 h post TBI. No difference is detected between the TBI group and TBI+vehicle group.

    ST 2825 purchased from MCE. Usage Cited in: Exp Neurol. 2017 May 18;295:23-35.

    Western blotting analysis of the Tyr1472-phosphorylation of the NR2B subunit in the hippocampus of experimental rats under the various treatment conditions. All rats are killed 90 min after Pilocarpine injection. IL-1β (1 ng in 2 μL) is injected 10 min before Pilocarpine. ST2825 (10 μg in 2 μL) is injected 20 min before Pilocarpine. Representative Western blotting bands corresponding to the specific proteins and the various pharmacological treatments.

    ST 2825 purchased from MCE. Usage Cited in: Anticancer Res. 2017 Nov;37(11):6203-6209.

    Effect of ST2825 on the expression of myeloid differentiation primary response gene 88 (MYD88) and nuclear factor kappa B (NF-ĸB) signaling proteins. Cells are cultured with 100 μM ST2825 for 6 h and analysed for protein expression by immunoblotting. DMSO is used as a vehicle control and α-tubulin as a loading control.

    ST 2825 purchased from MCE. Usage Cited in: Sci Rep. 2017 Nov 17;7(1):15797.

    Representative Western blot to show the level of MyD88 protein. The upper panel shows representative protein levels of MyD88. Tubulin is detected as a loading control. The bottom panel shows quantitative data of MyD88.
    • Biological Activity

    • Protocol

    • Technical Information

    • Purity & Documentation

    • References

    Description

    ST 2825 is a MyD88 homodimerization inhibitor.

    IC50 & Target

    MyD88[1]

    In Vitro

    ST2825 blocks IL-1R/TLR signaling by interfering with MyD88 homodimerization. ST2825 inhibits this interaction in a concentration-dependent manner with ~40% inhibition of dimerization at 5 μM ST2825 and 80% inhibition at 10 μM ST2825[1].

    In Vivo

    ST2825 dose-dependently inhibits IL-1β-induced production of IL-6 in treated mice after oral administration. The animals are administered orally with the appropriate vehicles or ST2825 at doses ranging from 50 to 200 mg/kg, 5 min prior to i.p. injection with 20 μg/kg IL-1β. ST2825 exertes a significant inhibition of IL-1β-stimulated production of IL-6 at 100 and 200 mg/kg[1].

    References
    Preparing Stock Solutions
    Concentration Volume Mass 1 mg 5 mg 10 mg
    1 mM 1.6906 mL 8.4529 mL 16.9059 mL
    5 mM 0.3381 mL 1.6906 mL 3.3812 mL
    10 mM 0.1691 mL 0.8453 mL 1.6906 mL
    Please refer to the solubility information to select the appropriate solvent.
    Cell Assay
    [1]

    ST2825 is dissolved in DMSO and stored, and then diluted with appropriate media (DMSO 0.1%) before use[1].

    HeLa cells are seeded at 105 cells/mL in a 96-well tissue-culture plate. After incubating overnight, the medium is discarded, and the cells are added with tissue culture medium, 10% FBS, containing ST2825 at concentrations ranging from 0.1 to 10 μM and DMSO at 0.1% final concentration. The cells are incubated for 6 and 18 h and then added with the yellow XTT (0.3 mg/mL) for further 2 h of incubation. At the end of the incubation periods, reactions are quantified by using a Sirio S Seac microplate reader[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Administration
    [1]

    ST2825 is administered orally as 0.5% suspension in carboxymethylcellulose (CMC)[1].

    Mice[1]
    Mice (female C57Bl/6) are divided into experimental groups of 15 mice. They are injected i.p. with saline (control animals) or recombinant murine IL-1β (20 μg/kg). A time-course analysis of IL-6 production established that the peak of cytokine is reached 2 h after IL-1β injection. ST2825, administered orally as 0.5% suspension in carboxymethylcellulose (CMC) or CMC alone, is supplied to the experimental mice groups. Two hours after IL-1β injection, the animals are killed, and sera are collected to assay IL-6 levels. Mice, which are treated orally with 100 and 200 mg/kg ST2825, shows lower levels of IL-6 versus CMC-treated mice. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    References
    Molecular Weight

    591.51

    Formula

    C₂₇H₂₈Cl₂N₄O₅S

    CAS No.

    894787-30-5

    SMILES

    O=C(N([[email protected]]1C(N)=O)[[email protected]@](SCC1)([H])C2)[[email protected]]2(CCC3)N3C(CC4=CC=C(C=C4)NC(COC(C(Cl)=C5)=CC=C5Cl)=O)=O

    Storage
    Powder -20°C 3 years
      4°C 2 years
    In solvent -80°C 6 months
      -20°C 1 month
    Shipping

    Room temperature in continental US; may vary elsewhere

    Solvent & Solubility

    10 mM in DMSO

    ST 2825 is dissolved in DMSO. ST2825 solution (0.5 μL) is administered via intracerebroventricular(ICV) injection at 15 min post-injury, using a 1 μL Hamilton microsyringe[4].
    ST 2825 is dissolved in 10% dimethyl sulfoxide in 0.1 M PBS[5].

    * "<1 mg/mL" means slightly soluble or insoluble. "≥" means soluble, but saturation unknown.

    References

    Purity: 99.51%

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product name

     

    Salutation

    Applicant name *

     

    Email address *

    Phone number *

     

    Organization name *

    Country *

     

    Requested quantity *

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    ST 2825
    Cat. No.:
    HY-50937
    Quantity: